Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013

Emerging Infectious Diseases

Volumn 20, Issue 9, 2014, Pages 1498-1503

  Pham, Cau D ^a   Reiss, Errol ^a   Hagen, Ferry ^b,c   Meis, Jacques F ^b,c   Lockhart, Shawn R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; ITRACONAZOLE; PYRROLE; STEROL 14ALPHA DEMETHYLASE; ANTIFUNGAL AGENT; CYTOCHROME P-450 CYP51A, ASPERGILLUS; CYTOCHROME P450; FUNGAL PROTEIN; PYRROLE DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DNA SEQUENCE; DRUG RESISTANCE; EPSILOMETER TEST; GENETIC ANALYSIS; GENOTYPE; GEOGRAPHIC DISTRIBUTION; LUNG LAVAGE; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM CULTURE; UNITED STATES; AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; DRUG EFFECTS; GENETICS; HEALTH SURVEY; HISTORY; HUMAN; MEDICAL GEOGRAPHY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION;

AMINO ACID SUBSTITUTION; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; AZOLES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FUNGAL PROTEINS; GEOGRAPHY, MEDICAL; HISTORY, 21ST CENTURY; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; POPULATION SURVEILLANCE; UNITED STATES;

EID: 84906279203     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2009.140142     Document Type: Article

References (40)

1. Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA. Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/ L98H mutation in the cyp51A gene. Antimicrob Agents Chemother. 2011;55:4465-8. http://dx.doi.org/10.1128/AAC.00185-11
2. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, et al. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol. 2009;47:3271-5. http://dx.doi.org/10.1128/JCM.00854-09
3. Bueid A, Howard SJ, Moore CB, Richardson MD, Harrison E, Bowyer P, et al. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009. J Antimicrob Chemother. 2010;65:2116-8. http://dx.doi.org/10.1093/jac/dkq279
4. Chowdhary A, Kathuria S, Randhawa HS, Gaur SN, Klaassen CH, Meis JF. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother. 2012;67:362-6. http://dx.doi. org/10.1093/jac/dkr443
5. Mortensen KL, Mellado E, Lass-Flörl C, Rodriguez-Tudela JL, Johansen SK, Arendrup MC. Environmental study of azoleresistant Aspergillus fumigatus and other aspergilli in Austria, Denmark, and Spain. Antimicrob Agents Chemother. 2010;54:4545-9. http://dx.doi.org/10.1128/AAC.00692-10
6. Seyedmousavi S, Hashemi SJ, Zibafar E, Hedayati MT, Mouton JW, Melchers WJ, et al. Azole-resistant Aspergillus fumigatus, Iran. Emerg Infect Dis. 2013;19:832-4. http://dx.doi.org/10.3201/ eid1905.130075
7. Burgel PR, Baixench MT, Amsellem M, Audureau E, Chapron J, Kanaan R, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother. 2012;56:869-74. http://dx.doi. org/10.1128/AAC.05077-11
8. European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species [cited 2013 Dec 1]. http://www.ecdc.europa. eu/en/publications/_layouts/forms/Publication_DispForm.aspx? ID=823&List=4f55ad51%2D4aed%2D4d32%2Db960%2Daf7011 3dbb90
9. Pfaller MA, Diekema DJ, Ghannoum MA, Rex JH, Alexander BD, Andes D, et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J Clin Microbiol. 2009;47:3142-6. http://dx.doi.org/10.1128/JCM.00940-09
10. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azoleresistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog. 2013;9:e1003633. http://dx.doi.org/10.1371/journal.ppat.1003633
11. Pham CD, Lockhart SR. An invisible threat: mutation-mediated resistance to triazole drugs in Aspergillus. Current Fungal Infection Reports. 2012;6:288-95. http://dx.doi.org/10.1007/s12281-012-0106-x
12. Escribano P, Recio S, Pelaez T, Bouza E, Guinea J. Aspergillus fumigatus strains with mutations in the cyp51a gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011;55:2460-2. http://dx.doi.org/10.1128/AAC.01358-10
13. van der Linden JW, Camps SM, Kampinga GA, Arends JP, Debets-Ossenkopp Y, Haas PJ, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013;57:513-20. http://dx.doi.org/10.1093/cid/cit320
14. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Azoleresistant Aspergillus fumigatus with the environmental TR46/Y121F/ T289A mutation in India. [Epub ahead of print]. J Antimicrob Chemother. 2014;69:555-7. http://dx.doi.org/10.1093/jac/dkt397
15. Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med. 2007;356:1481-3. http://dx.doi. org/10.1056/NEJMc061720
16. Denning DW, Park S, Lass-Flörl C, Fraczek MG, Kirwan M, Gore R, et al. High-frequency triazole resistance found in non-culturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis. 2011;52:1123-9. http://dx.doi.org/10.1093/cid/cir179
17. Morio F, Aubin GG, Danner-Boucher I, Haloun A, Sacchetto E, Garcia-Hermoso D, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother. 2012;67:1870-3. http://dx.doi.org/10.1093/jac/dks160
18. Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob Agents Chemother. 2008;52:2468-72. http://dx.doi. org/10.1128/AAC.00156-08
19. Camps SM, Rijs AJ, Klaassen CH, Meis JF, O'Gorman CM, Dyer PS, et al. Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol. 2012;50:2674-80. http://dx.doi.org/10.1128/ JCM.00335-12
20. Mortensen KL, Jensen RH, Johansen HK, Skov M, Pressler T, Howard SJ, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol. 2011;49:2243-51. http://dx.doi.org/10.1128/JCM.00213-11
21. Badali H, Vaezi A, Haghani I, Yazdanparast SA, Hedayati MT, Mousavi B, et al. Environmental study of azole-resistant Aspergillus fumigatus with TR34/L98H mutations in the cyp51A gene in Iran. Mycoses. 2013;56:659-63. http://dx.doi.org/10.1111/myc.12089
22. Snelders E, van der Lee HA, Kuijpers J, Rijs AJ, Varga J, Samson RA, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 2008;5:e219. http://dx.doi.org/10.1371/journal.pmed.0050219
23. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, Manning NJ, Stevens DA, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 1997;41:1364-8.
24. Bader O, Weig M, Reichard U, Lugert R, Kuhns M, Christner M, et al. cyp51A-Based mechanisms of Aspergillus fumigatus azole drug resistance present in clinical samples from Germany. Antimicrob Agents Chemother. 2013;57:3513-7. http://dx.doi.org/10.1128/ AAC.00167-13
25. Snelders E, Camps SM, Karawajczyk A, Schaftenaar G, Kema GH, van der Lee HA, et al. Triazole fungicides can induce crossresistance to medical triazoles in Aspergillus fumigatus. PLoS ONE. 2012;7:e31801. http://dx.doi.org/10.1371/journal.pone.0031801
26. United States Department of Agriculture. Agricultural chemical usage [cited 2013 Nov 1]. http://usda.mannlib.cornell.edu/MannUsda/ viewDocumentInfo.do;jsessionid=39589A84B623FFB18D319BF9 7277F79C?documentID=1560
27. Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. In vitro susceptibility testing of Aspergillus spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. J Clin Microbiol. 2003;41:1126-9. http://dx.doi. org/10.1128/JCM.41.3.1126-1129.2003
28. Klaassen CH, de Valk HA, Curfs-Breuker IM, Meis JF. Novel mixedformat real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother. 2010;65:901-5. http://dx.doi.org/10.1093/jac/dkq041
29. Pedley KF, Walton JD. Regulation of cyclic peptide biosynthesis in a plant pathogenic fungus by a novel transcription factor. Proc Natl Acad Sci U S A. 2001;98:14174-9. http://dx.doi.org/10.1073/ pnas.231491298
30. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disease Society of America. Clin Infect Dis. 2008;46:327-60. http://dx.doi.org/10.1086/525258
31. van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, et al. Clinical implications of azole resistance in Aspergillus fumigatus, the Netherlands, 2007-2009. Emerg Infect Dis. 2011;17:1846-54. http://dx.doi.org/10.3201/ eid1710.110226
32. Howard SJ, Cerar D, Anderson MJ, Albarrag A, Fisher MC, Pasqualotto AC, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis. 2009;15:1068-76. http://dx.doi.org/10.3201/eid1507.090043
33. Snelders E, Karawajczyk A, Schaftenaar G, Verweij PE, Melchers WJ. Azole resistance profile of amino acid changes in Aspergillus fumigatus cyp51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54:2425-30. http://dx.doi.org/10.1128/ AAC.01599-09
34. Chen J, Li H, Li R, Bu D, Wan Z. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother. 2005;55:31-7. http://dx.doi.org/10.1093/jac/dkh507
35. Mellado E, Garcia-Effron G, Alcazer-Fuoli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Substitutions at methionine 220 in the 14alpha-sterol demethylase (cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother. 2004;48:2747-50. http://dx.doi. org/10.1128/AAC.48.7.2747-2750.2004
36. Tashiro M, Izumikawa K, Minematsu A, Hirano K, Iwanaga N, Ide S, et al. Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother. 2012;56:584-7. http://dx.doi.org/10.1128/AAC.05394-11
37. Slaven JW, Anderson MJ, Sanglard D, Dixon GK, Bille J, Roberts IS, et al. Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol. 2002;36:199-206. http://dx.doi.org/10.1016/S1087-1845(02)00016-6
38. Bowyer P, Mosquera J, Anderson M, Birch M, Bromley M, Denning DW. Identification of novel genes conferring altered azole susceptibility in Aspergillus fumigatus. FEMS Microbiol Lett. 2012;332:10-9. http://dx.doi.org/10.1111/j.1574-6968.2012.02575.x
39. da Silva Ferreira ME, Capellaro JL, dos Res Marques E, Malavazi I, Perlin D, Park S, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother. 2004;48:4405-13. http://dx.doi. org/10.1128/AAC.48.11.4405-4413.2004
40. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571-81. http://dx.doi.org/10.1128/JCM.00308-13